Clinical trials: Eye Diseases, Hereditary
Congenital Glaucoma
Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma
The objective of this prospective randomised study is to compare the efficacy and safety of ologen CM (Collagen matrix) as adjunct to combined trabeculotomy-trabecuectomy in congenital glaucoma cases, the efficacy being the…
- Trial name
- NCT02121171
- Testing
- Ologen Collagen Matrix, Combined trabeculotomy-trabeculectomy
- Where
- Azerbaijan
- Volunteers
- 40 people
- Sponsor
- National Centre of Ophthalmology named after academician Zarifa Aliyeva
Retinitis Pigmentosa Syndrome
Evaluation of the Visual Field on the Ground
Retinopathy pigmentosa (which affects about 40,000 patients in France) leads to destruction of the peripheral retina. This condition, often familial, frequently affects young patients.
- Trial name
- ECVS (NCT03989622)
- Testing
- evaluation of the visual field on the ground
- Sponsor
- University Hospital, Limoges
Attempted Suicide, Depression
Culturally Adapted Cognitive Behavioral Therapy for Prevention of Self Harm
Aim: To adapt and develop a culturally appropriate psychological intervention and test its feasibility, and acceptability for the patients presenting to general hospital following self-harm in Karachi Pakistan.
- Trial name
- NCT01308151
- Testing
- Other
- Where
- 4 sites in Pakistan
- Volunteers
- 221 people
- Sponsor
- Pakistan Institute of Living and Learning
Eye Diseases, Macular Degeneration
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis™ in patients with…
- Conditions
- Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration
- Trial name
- NCT02543229
- Testing
- OPT-302, Lucentis™
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Opthea Limited
Retinitis Pigmentosa
A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa
The purpose of this first-in-human study is to explore the maximum tolerated dose (MTD) of CPK850 as determined by the single ascending dose ranging portion of the study.
- Trial name
- NCT03374657
- Testing
- CPK850
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Fuchs' Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy
Prognosis of Posterior Lamellar Keratoplasty
Over the past decade, the management of Fuchs' endothelial corneal dystrophy (FECD) and pseudophakic bullous keratopathy (PBK) has been revolutionized by the development of posterior lamellar keratoplasty techniques: DSAEK and…
- Trial name
- CORNEACOHORT (NCT06859411)
- Testing
- visual acuity comparaison
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Retinitis Pigmentosa, Dry Age-related Macular Degeneration
CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
The study will provides the enrollment of patients with genetic retinal dystrophies with primary rod impairment and dry age-related macular degeneration (Geographic type) A subretinal injection of umbilical cord blood…
- Trial name
- SiCord (NCT04636853)
- Testing
- Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Takayasu Arteritis, Behcet Disease
Turkish Adaptation of the VascuQoL-6 Quality of Life Scale
Study type: Observational study Primary objective: The aim of this study was to examine the validity and reliability of the Vascular Quality of Life Questionnaire-6 (VascuQoL-6) in Turkish in individuals diagnosed with Takayasu…
- Conditions
- Takayasu Arteritis, Behcet Disease, Quality of Life
- Trial name
- NCT06979245
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 37 people
- Sponsor
- Uşak University
Fuchs' Endothelial Dystrophy, Pseudophakic Bullous Keratopathy
The Effect Of Preoperative Parameters On Success After DMEK Surgery
The aim of this study is to evaluate the effect of preoperative parameters on surgical results in Descemet Membrane Endothelial Keratoplasty (DMEK) surgery.
- Conditions
- Fuchs' Endothelial Dystrophy, Pseudophakic Bullous Keratopathy, Descemet's Membrane; Defect, Herpetic Keratitis
- Trial name
- NCT04420429
- Testing
- Descemet membrane endothelial keratoplasty (DMEK)
- Where
- Turkey (Türkiye)
- Volunteers
- 43 people
- Sponsor
- Beyoglu Eye Research and Education Hospital
Graves Ophthalmopathy
Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease
Thyroid eye disease is an autoimmune disorder affecting approximately 50% of individuals with autoimmune thyroid diseases resulting in enlargement of ocular muscles and may lead to congestion of the eyelids and ocular surface…
- Trial name
- CRISEPTED (NCT02339142)
- Testing
- External beam radiotherapy, intravenous corticosteroids (methylprednisolone)
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Corneal Edema
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.
- Trial name
- Fuchs (NCT04498169)
- Testing
- Netarsudil Ophthalmic
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aerie Pharmaceuticals
Healthy
Oat Phenolics Bioavailability
A diet rich in whole grain is inversely associated with cardiovascular disease risk and this benefit could be partly attributed to the phenolic acid content of whole grains.
- Trial name
- NCT02574039
- Testing
- Oat bran, refined grain
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Reading
Behçet Disease
Dusquetide for the Treatment of Behcet's Disease
This is a clinical study to see if dusquetide can treat flares of oral and genital ulcers caused by Behcet's Disease. Study participants will receive an infusion of dusquetide twice a week for 4 weeks (8 treatments total), with…
- Trial name
- NCT06386744
- Testing
- Dusquetide
- Where
- Turkey (Türkiye)
- Volunteers
- 8 people
- Sponsor
- Soligenix
Stargardt Disease, Stargardt Macular Dystrophy
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye.
- Conditions
- Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
- Trial name
- DEVOTE (NCT07734064)
- Testing
- ASP2020
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Retinoblastoma
Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation
The purpose of this study is to determine whether 3 cycles of chemotherapy(CEV) is not inferior to 6 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.
- Trial name
- NCT01906814
- Testing
- 3 cycles chemotherapy, 6 cycles chemotherapy
- Where
- China
- Volunteers
- 179 people
- Sponsor
- Sun Yat-sen University
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma
- Trial name
- NCT00831844
- Testing
- cixutumumab, laboratory biomarker analysis
- Where
- 105 sites in United States, Australia and 1 more
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Leber Congenital Amaurosis 10, Blindness
Extension Study to Study PQ-110-001 (NCT03140969)
Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders
- Trial name
- INSIGHT (NCT03913130)
- Testing
- QR-110
- Where
- 3 sites in United States, Belgium
- Volunteers
- 9 people
- Sponsor
- Laboratoires Thea
Retinopathy of Prematurity, Preterm Infants
An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
This is an observational study in which only data from babies with retinopathy of prematurity (ROP) who are being treated with aflibercept (Eylea) in prefilled syringe (PFS) using a paediatric dosing device (PDD) are collected…
- Trial name
- NCT06315556
- Testing
- Aflibercept (Eylea)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Bayer
Retinal Dystrophy, Cone-Rod, Cone Dystrophy
Study of New Mutations in Cone Disorders
High throughput sequencing gives the opportunity to improve the genetic diagnosis for patients suffering from retinal dystrophies and specially from cone disorders.
- Conditions
- Retinal Dystrophy, Cone-Rod, Cone Dystrophy, Cone Rod Dystrophy, Macular Degeneration
- Trial name
- INTROCONE (NCT04658251)
- Testing
- Blood and/or skin biopsy
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Lille
Fuchs, Fuchs Dystrophy
Descemet Endothelial Thickness Comparison Trial II
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping…
- Conditions
- Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
- Trial name
- DETECT II (NCT05275972)
- Testing
- Ripasudil
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.